In ovarian cancer, XIST promotes the stability of lysine (K)-specific methyltransferase 2C (KMT2C) mRNA, thereby indirectly promoting histone H3 methylation at lysine 4 and hence decreasing CSC proliferation [145]. Here, KMT2C is linked to ovarian carcinoma.